Trial Search Results

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether giving monoclonal antibody therapy is more effective than a placebo in treating patients with ovarian epithelial, fallopian tube, or peritoneal cancer who have responded to surgery and chemotherapy.

PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients with residual disease from stage III or stage IV ovarian epithelial, fallopian tube, or peritoneal cancer following surgery and chemotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

AltaRex

Stanford Investigator(s):

Intervention(s):

  • Biological: oregovomab

Phase:

Phase 2

Eligibility


DISEASE CHARACTERISTICS: Histologically proven stage III or IV ovarian epithelial, tubal,
or peritoneal adenocarcinoma Must have had complete clinical response to primary therapy
consisting of surgical debulking and platinum based chemotherapy Elevated CA 125 (greater
than 35 U/mL) prior to or at surgery (if presurgical CA 125 measurement is not available,
patient must have a serum CA 125 of at least 100 U/mL and strong tumor tissue expression)
Must have residual disease (visible or palpable) at completion of the staging laparotomy
(IIIB and IIIC microscopic disease)

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Karnofsky 60-100%
Life expectancy: At least 6 months Hematopoietic: Hemoglobin at least 8.0 g/dL Lymphocyte
count at least 300/mm3 Neutrophil count at least 1,000/mm3 Platelet count at least
100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal Renal:
Creatinine no greater than 1.6 mg/dL

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy No
prior murine monoclonal antibodies for diagnostic or therapeutic purposes Chemotherapy: No
more than 1 prior regimen of chemotherapy (change in chemotherapy agents is permitted
during primary therapy provided that the change is considered to be part of initial
chemotherapy regimen) At least 4 weeks since prior chemotherapy Endocrine therapy: Not
specified Radiotherapy: At least 4 weeks since prior abdominal, abdominopelvic, or pelvic
radiotherapy Surgery: At least 4 weeks since prior surgery No more than 1 interval
debulking procedure

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting